Figure 2.

Anti-CD3-treated IRBP161–180-immunized B10RIII mice show a decreased T cell response to the immunizing peptide. (A), Two groups of IRBP161–180-immunized B10RIII mice (n=5) were treated with or without 50 μg of anti-CD3 mAb on days 6–10, then, on day 14, enriched splenic and LN T cells were pooled, stimulated with the immunizing peptide for 2 days in the presence of syngeneic APCs, and tested for their proliferative response in the presence of graded doses of IRBP161–180 and irradiated APCs from B10RIII mice. Shown is the means ± SD, a representative experiment of two with similar results. (B), Supernatants from the above cultures were collected and tested for IFN-γ, IL-17, and IL-6 released by IRBP-specific T cells by ELISA. The results shown are the means ± SD [n=5] and are representative of those in two experiments. (C), Two groups (n =4) of naïve B10RIII mice were adoptively transferred with 5 × 10⁶ in vitro Ag-stimulated T cells isolated on day 14 from IRBP161–180 immunized mice treated with or without anti-CD3 mAb on days 6–10. Disease was monitored and scored twice a week by fundoscopy from day 6 after transfer till day 50. The data reflect two combined experiments with four mice per group. Score for each mouse is an average of both eyes. The results shown are the mean ± SD for the 8 mice.